• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRX alert in real time by email
    SC 13G/A 1 cormorant-imrx093024a4.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*



    Immuneering Corporation

    (Name of Issuer)

     

    Class A Common Stock

    (Title of Class of Securities)

     

    45254E107

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  45254E107
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Cormorant Asset Management, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     
     


     

    CUSIP No.  45254E107
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Bihua Chen
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IN
     
     


     

     

    CUSIP No. 45254E107
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Immuneering Corporation

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    245 Main St., Second Floor

    Cambridge, MA 02142

    Item 2.(a) Names of Person Filing:

    Cormorant Asset Management, LP

    Bihua Chen

    This statement is filed by (i) Cormorant Asset Management, LP ("Cormorant"), a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the Cormorant Funds and (ii) Bihua Chen ("Ms. Chen") with respect to the Shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 2.(b) Address of Principal Business Office:

    200 Clarendon Street, 52nd Floor

    Boston, MA 02116

     

    Item 2.(c) Citizenship:

    Cormorant Asset Management, LP - Delaware

    Bihua Chen - United States

     

    Item 2.(d) Title of Class of Securities

    Class A Common Stock (the "Shares")

     

    Item 2.(e) CUSIP No.:

    45254E107

     

    CUSIP No.  45254E107
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨

    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

          Not Applicable

     

    CUSIP No. 45254E107
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned

    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

    (b) Percent of class

    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    (ii) Shared power to vote or to direct the vote

    (iii) Sole power to dispose or to direct the disposition of

    (iv) Shared power to dispose or to direct the disposition of

    The information set forth in Rows 5 though 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a -11.

     

     
    CUSIP No. 45254E107
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           

     

     
    CUSIP No. 45254E107
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           
    Get the next $IMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMRX

    DatePrice TargetRatingAnalyst
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    3/15/2024$20.00 → $15.00Buy
    Needham
    3/15/2024Outperform → Market Perform
    TD Cowen
    3/15/2024$16.00 → $3.00Buy → Hold
    Jefferies
    12/1/2023$20.00Buy
    Needham
    6/26/2023$25.00Outperform
    Oppenheimer
    4/19/2023$5.00 → $14.00Underweight → Equal-Weight
    Morgan Stanley
    4/19/2023$10.00 → $20.00Neutral → Buy
    Mizuho
    More analyst ratings

    $IMRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

      - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE

      5/7/24 4:05:00 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

      CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization

      3/12/24 8:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

      - Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predicted - - Study timeline for IMM-1-104 accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024- - Pharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected - - Completed $30 million underwritten offering; Projected cash runway extended into 2025 - CAMBRIDGE, Mass., May

      5/4/23 4:05:00 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Immuneering Corporation

      10-Q - Immuneering Corp (0001790340) (Filer)

      5/5/25 4:34:07 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Immuneering Corp (0001790340) (Filer)

      5/5/25 4:17:28 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Immuneering Corporation

      S-8 - Immuneering Corp (0001790340) (Filer)

      5/5/25 4:16:16 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Immuneering Corporation downgraded by Morgan Stanley

      Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight

      12/13/24 8:04:38 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Immuneering Corporation with a new price target

      Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      3/15/24 7:50:35 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Corporation downgraded by TD Cowen

      TD Cowen downgraded Immuneering Corporation from Outperform to Market Perform

      3/15/24 7:19:50 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

      - Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q'25 - - Reported positive data from the Company's ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer, and as monotherapy in second-line pancreatic cancer - - Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Named industry veteran Dr. Igor Matushansky as Chief Medical Officer, to lead clinical efforts as t

      5/5/25 4:05:00 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

      CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Igor Matushansky, Chief Medical Officer, Harold "E.B." Brakewood, Chief Business Officer, Michael Bookman, Chief Legal Officer, Secretary and Mallory Mora

      4/2/25 8:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Corporation Announces Grant of Inducement Award

      CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D., Ph.D., was named Chief Medical Officer of the Company. In connection with the commencement of Dr. Matushanky's employment, on March 21, 2025, Dr. Matushanky was granted an option to purchase 118,000 shares of the Company's Class A common stock with a per share exercise price of $1.80, the closing trading price of the Company's Class A common stock on the Nasdaq Global Market on March 21, 2025. Th

      3/21/25 4:30:09 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 4 filed by Chief Medical Officer Matushansky Igor

      4 - Immuneering Corp (0001790340) (Issuer)

      3/24/25 4:12:04 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Matushansky Igor

      3 - Immuneering Corp (0001790340) (Issuer)

      3/24/25 4:05:25 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Morales Mallory

      4 - Immuneering Corp (0001790340) (Issuer)

      2/7/25 4:25:17 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schall Thomas J. bought $7,385 worth of shares (2,900 units at $2.55) (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      3/25/24 4:03:33 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Feinberg Peter bought $63,713 worth of shares (25,000 units at $2.55), increasing direct ownership by 29% to 111,766 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      3/25/24 9:13:49 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brakewood Harold Eugene bought $10,015 worth of shares (3,900 units at $2.57) (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      3/25/24 9:10:03 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      11/14/24 4:15:35 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      11/14/24 3:03:47 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      4/15/24 6:10:57 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Financials

    Live finance-specific insights

    See more
    • Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

      - Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial data for IMM-1-104 monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled acros

      1/7/25 7:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

      - In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment - - Initial data are at 240 mg QD (safety lead-in dose) of IMM-1-104; additional patients have now been dosed at 320 mg QD in this arm; IMM-1-104 has been well-tolerated to date in combination with gemcitabine/nab-paclitaxel - - Initial data are consistent with preclinical data presented at AACR, which demonstrated that IMM-1-104 combined with chemotherapy induced deeper res

      9/12/24 4:05:00 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

      - IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, supporting goal of Universal-RAS activity - - Target lesion regression observed in over half of patients treated with IMM-1-104 at 320mg or 240mg QD, with best individual lesion regression of -35.7% and best RECIST sum of longest diameters (SLD) of -18.9%, both at 320mg - - Candidate RP2D of 320 mg QD supported by tolerability, PK/PD, ctDNA results & initial anti-tumor activity - - Phase 2a portion of the study underway with three monotherapy and two combin

      3/14/24 7:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care